Larimar Therapeutics Inc (LRMR)
$7.49
Live
Performance
- $7.41$7.94$7.49
1.06%
Downside
Day's Volatility :6.67%
Upside
5.67%
- $2.18$13.68$7.49
70.89%
Downside
52 Weeks Volatility :84.06%
Upside
45.25%
Returns
| Period | Larimar Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -17.97% | 0.0% |
6 Months | 21.25% | 0.0% |
1 Year | 175.18% | 0.0% |
3 Years | -37.92% | -23.0% |
Highlights
Market Capitalization | 500.9M |
Book Value | $3.31 |
Earnings Per Share (EPS) | -1.12 |
Wall Street Target Price | 21.8 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -23.59% |
Return On Equity TTM | -37.48% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -65.5M |
Diluted Eps TTM | -1.12 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.4 |
EPS Estimate Next Year | -1.86 |
EPS Estimate Current Quarter | -0.3 |
EPS Estimate Next Quarter | -0.33 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 191.05%
Technicals Summary
Sell
Neutral
Buy
Larimar Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Larimar Therapeutics Inc | 19.75% | 21.25% | 175.18% | -37.92% | -36.91% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Larimar Therapeutics Inc | NA | NA | NA | -1.4 | -0.37 | -0.24 | NA | 3.31 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Larimar Therapeutics Inc | Buy | $500.9M | -36.91% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Larimar Therapeutics Inc
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 82.7%
Institutional Holdings
Deerfield Management Co
33.28%RA Capital Management, LLC
9.47%HHG PLC
6.86%Goldman Sachs Group Inc
6.79%Blue Owl Capital Holdings LP
6.05%BlackRock Inc
4.91%
Company Information
larimar therapeutics, inc. (nasdaq:lrmr), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. the company’s lead compound, cti-1601, is currently being evaluated in a phase 1 clinical program as a potential treatment for friedreich’s ataxia, a rare and progressive genetic disease. larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. for more information, please visit: https://larimartx.com.
Organization | Larimar Therapeutics Inc |
Employees | 42 |
CEO | Dr. Carole S. Ben-Maimon M.D. |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$7.49
-3.48%
Invesco Bulletshares 2025 Hi
$7.49
-3.48%
Schwab International Dividend Equity Etf
$7.49
-3.48%
Blockchain Coinvestors Acquisition Corp.
$7.49
-3.48%
Allgiant Travel Company
$7.49
-3.48%
Rogers Corp
$7.49
-3.48%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$7.49
-3.48%
Iheartmedia
$7.49
-3.48%
Lightpath Technologies Inc
$7.49
-3.48%